As of Aug. 27, 2026, three health care stocks are overbought and could be giving a real warning to m

Bank of America Corp DE raised its holdings in shares of Pulse Biosciences, Inc (NASDAQ: PLSE) by 8.

Pulse Biosciences, Inc (NASDAQ: PLSE - Get Free Report) shares reached a new 52-week high during tra

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its n

Top Wall Street analysts changed their outlook on top stocks. See analyst ratings and price targets

WALL analysts changed outlook on top names. See upgrades, downgrades & initiations on analyst ra

Top Wall Street analysts changed outlook on top names. See analyst rating changes on Benzinga's

Needham analyst Mike Matson initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rati

Pulse Biosciences NASDAQ: PLSE is positioning its nanosecond pulsed field ablation technology as a p

Canaccord Genuity analyst William Plovanic maintains Pulse Biosciences (NASDAQ:PLSE) with a Buy a

Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript

Pulse Biosciences NASDAQ: PLSE reported second-quarter revenue of $434,000 as it accelerated clinica

Pulse Biosciences, Inc (PLSE) came out with a quarterly loss of $0.36 per share versus the Zacks Con

Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.36) per share which met the analyst

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its n

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its n

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its n

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its n

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its n

Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected f

Pulse Biosciences, Inc. (PLSE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 20

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its n

Canaccord Genuity analyst William Plovanic initiates coverage on Pulse Biosciences (NASDAQ:PLSE)

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ techn

Does Pulse Biosciences, Inc (PLSE) have what it takes to be a top stock pick for momentum investors?

Pulse Biosciences, a developer of non-thermal bioelectric treatments, reported a notable insider buy

Pulse Biosciences, Inc. (PLSE) Presents at Bank of America Global Healthcare Conference 2026 Prepare

Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary nanosecond

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ techn

Pulse Biosciences NASDAQ: PLSE said it is sharpening its focus on its nanosecond pulsed field ablati

Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.27) per share which beat the analys

The first seven patients in this study were treated at St. Bernards Medical Center in Jonesboro, Ark

Pulse Biosciences, Inc. (NASDAQ:PLSE), pioneer of the novel nPulse™ platform using proprietary Nanos

Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using its proprieta

Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.26) per share which beat the analys

Pulse Biosciences stock rises after new study data showed strong early results for its heart treatme

Pulse Biosciences stock trading higher on promising clinical data for atrial fibrillation treatment,

U.S. stocks were higher, with the Dow Jones index gaining more than 700 points on Friday.

Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a comp

Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.29) per share which beat the analys

First U.S. Surgical Treatments with PFA Clamp for Patients with Atrial Fibrillation During Concomita

Successfully treated atrial fibrillation (AF) in initial 30 patients with the nPulse™ Cardiac Surgic

Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pul